$1.91-0.03 (-1.55%)
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
Sera Prognostics, Inc. in the Healthcare sector is trading at $1.91. The stock is currently near its 52-week low of $1.37, remaining 32.0% below its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why SERA maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test...
Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are HRB, SPWH, SERA, VEEV and WKHS.
Moby summary of Sera Prognostics, Inc.'s Q4 2025 earnings call
Sera Prognostics Inc (SERA) reports a mixed quarter with declining revenue but strategic advancements in state engagement and European market entry.
Sera Prognostics (NASDAQ:SERA) executives emphasized progress in evidence generation and early commercialization efforts during the company’s fourth-quarter and full-year 2025 earnings call, held March 18, 2026. Management highlighted the publication of its pivotal PRIME study, a growing pipeline of